EU/3/20/2382: Orphan designation for the treatment of patients with Olmsted syndrome

erlotinib

Overview

On 9 December 2020, orphan designation EU/3/20/2382 was granted by the European Commission to Institut Des Maladies Génétiques, France, for erlotinib for the treatment of Olmsted syndrome.

 

Key facts

Active substance
erlotinib
Intented use
Treatment of patients with Olmsted syndrome
Orphan designation status
Positive
EU designation number
EU/3/20/2382
Date of designation
09/12/2020
Sponsor

Laboratoires C.T.R.S.
63 Rue de l’ Est 
92100 Boulogne Billancourt 
France 
E-mail: olmsted-eu@ctrs.fr

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

DateUpdate
December 2021The sponsorship was transferred to Laboratoires C.T.R.S., France.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating